SEC Form 4 · accession 0001636282-26-000084
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Thomas Henderson
Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 23, 2026 · 9:32 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | S | 20,000 | $100.00 | D | 68,606 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.